Background and purpose There is still no curative treatment for multiple sclerosis (MS), but
during the last 20 years eight different disease‐modifying compounds have been approved …

Objective To compare treatment efficacy and persistence in patients who switched to
natalizumab versus those who switched between glatiramer acetate (GA) and interferon …

Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …

Importance After multiple sclerosis (MS) relapse while a patient is receiving an injectable
disease-modifying drug, many physicians advocate therapy switch, but the relative …

Objective To review evidence on starting, switching, and stopping disease-modifying
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing …

Background Options for non-responders to relapsing–remitting multiple sclerosis (RRMS)
first-line disease-modifying therapies (DMT) are limited. We explored whether switching first …

Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for
treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of …

Background and Objectives B cell–depleting therapies are highly effective in relapsing-
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous
system (CNS). It predominantly affects young women and is one of the most common causes …

Background Several disease-modifying therapies (DMTs) treat relapsing–remitting multiple
sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Few comprehensive …